Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF35700 long-term safety in schizophrenia
NCT02892422Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Aug 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of lu af35700 in schizophrenia, sponsored by Lundbeck. Primary endpoint: Treatment-Emergent Adverse Events at 57 weeks. Started Aug 2016; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02892422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02892422.